Skip to main content
. 2019 Dec 20;10:2856. doi: 10.3389/fimmu.2019.02856

Figure 3.

Figure 3

Real-life setting data on the use of blinatumomab for B-cell ALL. (A) Overall treatment of the patients before blinatumomab. (B) OS for patients treated with blinatumomab in Romania. (C) RFS for patients treated with blinatumomab in Romania.